(Q42547622)

2 November 2017

title

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization (English)

1 reference

2 November 2017

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization (English)

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

16 November 2024

0 references

1 reference

B. M. Kenyon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9301478

16 November 2024

F. Browne

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9301478

16 November 2024

R. J. D'Amato

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9301478

16 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9301478

16 November 2024

publication date

1 June 1997

1 reference

2 November 2017

June 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9301478

full work available at URL

16 November 2024

https://api.elsevier.com/content/article/PII:S001448359790292X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

https://api.elsevier.com/content/article/PII:S001448359790292X?httpAccept=text/plain

16 November 2024

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Experimental Eye Research

16 November 2024

published in

1 reference

2 November 2017

volume

64

1 reference

2 November 2017

issue

6

1 reference

2 November 2017

page(s)

971-978

1 reference

EVALUATION OF THE TERATOGENICITY OF DRUGS.

2 November 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

16 November 2024

3

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Thalidomide is an inhibitor of angiogenesis

16 November 2024

4

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The fate of[14C]thalidomide in the pregnant rabbit

16 November 2024

5

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Toxicity and Teratogenicity of Optical Isomers of Thalidomide

16 November 2024

6

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

16 November 2024

7

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Effect of Thalidomide on the Graft versus Host Reaction

16 November 2024

8

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

16 November 2024

9

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy

16 November 2024

10

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas

16 November 2024

11

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The effect of thalidomide and supidimide on endotoxin-induced uveitis in rats

16 November 2024

12

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Embryotoxic effects of thalidomide derivatives in the non-human primate callithrix jacchus. IV. Teratogenicity of micrograms/kg doses of the EM12 enantiomers

16 November 2024

13

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Chirality in antirheumatic drugs

16 November 2024

15

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Teratogenic activity of a hydrolytic thalidomide metabolite in mice

16 November 2024

17

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

THALIDOMIDE AND CONGENITAL ABNORMALITIES

16 November 2024

19

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

16 November 2024

20

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide

16 November 2024

21

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects

16 November 2024

22

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

16 November 2024

23

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The enantiomers of the teratogenic thalidomide analogue EM 12: 1. Chiral inversion and plasma pharmacokinetics in the marmoset monkey

16 November 2024

25

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The enantiomers of the teratogenic thalidomide analogue EM 12. 2. Chemical stability, stereoselectivity of metabolism and renal excretion in the marmoset monkey.

16 November 2024

26

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo

16 November 2024

27

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution

16 November 2024

28

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species

16 November 2024

29

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The teratogenic activity of a thalidomide analogue, EM 12 in rabbits, rats, and monkeys.

16 November 2024

32

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Further Observation with Thalidomide in Lepra Reactions

16 November 2024

34

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide

16 November 2024

35

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor

16 November 2024

36

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

Thalidomide for the treatment of chronic graft-versus-host disease

16 November 2024

39

1 reference

https://api.crossref.org/works/10.1006/EXER.1997.0292

16 November 2024

Identifiers

1 reference

2 November 2017

1 reference